| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 421 Halland |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 73 | 11.8% | 23 | 3.7% | 13 | 2.1% | 1 | 0.2% | 1 | 0.2% | . | . | 509 | 82.1% | 620 | 100.0% |
| ASCUS | 198 | 48.2% | 114 | 27.7% | 65 | 15.8% | 1 | 0.2% | . | . | . | . | 33 | 8.0% | 411 | 100.0% |
| LSIL | 45 | 30.2% | 52 | 34.9% | 35 | 23.5% | . | . | . | . | . | . | 17 | 11.4% | 149 | 100.0% |
| Atypical glandular cells/AGC | . | . | 1 | 12.5% | . | . | 5 | 62.5% | 2 | 25.0% | . | . | . | . | 8 | 100.0% |
| Unclear atypia | 2 | 25.0% | 1 | 12.5% | 5 | 62.5% | . | . | . | . | . | . | . | . | 8 | 100.0% |
| ASC-H | 17 | 21.8% | 10 | 12.8% | 51 | 65.4% | . | . | . | . | . | . | . | . | 78 | 100.0% |
| HSIL | 2 | 5.0% | 1 | 2.5% | 36 | 90.0% | . | . | 1 | 2.5% | . | . | . | . | 40 | 100.0% |
| Totalt | 337 | 25.6% | 202 | 15.4% | 205 | 15.6% | 7 | 0.5% | 4 | 0.3% | . | . | 559 | 42.5% | 1314 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M80703, M81403 |